Back to top

Real Time Insight

The activist investor is one that has received a whole lot of press lately. We used to call them corporate raiders, but let's leave the football team from Oakland out of the discussion for now.

Activists - or investors that are looking to take an active role on the board of directors - try to unlock value that they believe is being hidden by the company.

One of the recent activists is Dan Loeb and his hedge fund Third Point, which famously took on the board of directors at Yahoo!. He was able to remove the chairmen of the board and several other directors while helping to secure a headline grabbing CEO in Marissa Mayer.

Bill Ackman is another example of an investor who helps make changes at the company he invests in. Canadian Pacific Railway is one of his bigger wins, but Herbalife (HLF - Snapshot Report) is certainly the play that Ackman will be associated with going forward.

Fail Whale

Despite all these triumphs for the investing community, we have several failures out there as well. I know it seems like I am picking on Carl Icahn, but let's face it, he could care less what I write.

Carl has seen numerous tech related activists roles end up in failure. He went after Yahoo! long before Loeb did so and enacted change. Icahn made a play for Dell before he eventually withdrew and Dell went private. And now we have the failed bid to get Apple to increase its buyback to $145B --- settling for the idea of coming close to a $50B buyback

It should be noted that AAPL is up about $10 per share today, as Icahn has backed off, and up about 3.2% over the last three trading sessions.

Hit or Miss

Knowing this, are you more or less likely to invest in a stock that is seeing activist involvement?

Chime in below and let us know what you think!

Just Released: 5 Stocks Set to Double

Today, you are invited to download a free Special Report from Zacks Investment Research. It reveals five moves that could gain +100% and more in the next 12 months:

One company announced a cancer breakthrough that scored a 79% increase in progression-free survival in Phase III testing. Another is set to gain steam from a $3.45 billion acquisition. Still another has room for price increases that could send margins through the roof.

Close This Panel X

Please login to or register to post a comment.